UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Blood, 2003-06, Vol.101 (12), p.4944-4951

2003

Volltextzugriff (PDF)

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Blood, 1996-01, Vol.87 (2), p.567-573

1996

Volltextzugriff (PDF)

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

Blood, 2005-03, Vol.105 (6), p.2473-2479

2005

Volltextzugriff (PDF)

More ZAP for chronic lymphocytic leukemia (CLL)

Blood, 2005-03, Vol.105 (5), p.1839-1840

Wiestner, Adrian

2005

Volltextzugriff (PDF)

Rituximab in the treatment of acquired factor VIII inhibitors

Blood, 2002-11, Vol.100 (9), p.3426-3428

2002

Volltextzugriff (PDF)

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

Blood, 2004-09, Vol.104 (5), p.1428-1434

2004

Volltextzugriff (PDF)

Thrombopoietin Production Is Inhibited by a Translational Mechanism

Blood, 1998-12, Vol.92 (11), p.4023-4030

1998

Volltextzugriff (PDF)

Thrombopoietin production is inhibited by a translational mechanism

Blood, 1998-12, Vol.92 (11), p.4023-4030

1998

Volltextzugriff (PDF)

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

Blood, 2012-12, Vol.120 (24), p.4684-4691

Wiestner, Adrian

2012

Volltextzugriff (PDF)

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Blood, 2011-01, Vol.117 (1), p.26-38

2011

Volltextzugriff (PDF)

Predicting treatment outcomes in CLL

Blood, 2014-05, Vol.123 (21), p.3212-3214

Wiestner, Adrian

2014

Volltextzugriff (PDF)

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood, 2017-03, Vol.129 (11), p.1469-1479

2017

Volltextzugriff (PDF)

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood, 2018-05, Vol.131 (21), p.2357-2366

2018

Volltextzugriff (PDF)

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Blood, 2016-10, Vol.128 (15), p.1940-1943

2016

Volltextzugriff (PDF)

Targeting C3d in Combination with Daratumumab:a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.9989-9990

2022

Volltextzugriff (PDF)

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Blood, 2018-08, Vol.132 (5), p.521-532

2018

Volltextzugriff (PDF)

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Blood, 2023-11, Vol.142 (Supplement 1), p.4196-4196

2023

Volltextzugriff (PDF)

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Blood, 2019-05, Vol.133 (22), p.2452-2455

2019

Volltextzugriff (PDF)

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Blood, 2021-01, Vol.137 (2), p.185-189

2021

Volltextzugriff (PDF)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Blood, 2022-11, Vol.140 (Supplement 1), p.9896-9897

2022

Volltextzugriff (PDF)

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Blood, 2022-11, Vol.140 (Supplement 1), p.9847-9848

2022

Volltextzugriff (PDF)

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Blood, 2022-11, Vol.140 (Supplement 1), p.4169-4170

2022

Volltextzugriff (PDF)

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Blood, 2022-11, Vol.140 (Supplement 1), p.10255-10256

2022

Volltextzugriff (PDF)

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Blood, 2014-05, Vol.123 (21), p.3286-3295

2014

Volltextzugriff (PDF)

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Blood, 2023-11, Vol.142 (Supplement 1), p.1891-1891

2023

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(160)

Publikationsform

Artikel
(165)

Sprache

Englisch
(165)
Japanisch
(8)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

More ZAP for chronic lymphocytic leukemia (CLL)

Rituximab in the treatment of acquired factor VIII inhibitors

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

Thrombopoietin Production Is Inhibited by a Translational Mechanism

Thrombopoietin production is inhibited by a translational mechanism

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Predicting treatment outcomes in CLL

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Targeting C3d in Combination with Daratumumab:a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Aktive Filter

Suchergebnisse filtern